Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04007276 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jun 1, 2031 → Nov 2031
See other at-risk trials from Tulane University

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Nov 10, 2026 to Nov 2027
    • Primary completion pushed from Jun 1, 2031 to Nov 2031
    • Study completion pushed from Jun 1, 2036 to Nov 2036
    • Eligibility criteria expanded, about 12 words
  2. Primary completion date: Jun 1, 2030 to Jun 1, 2031
    • Start date: Nov 10, 2025 to Nov 10, 2026
    • Study completion date: Jun 1, 2035 to Jun 1, 2036
    v8
  3. 3 versions Re-verified since Apr 4, 2022, no change to tracked fieldsv5-v7
  4. Primary completion date: Jun 1, 2020 to Jun 1, 2030
    • Start date: Nov 10, 2019 to Nov 10, 2025
    • Study sites: 0 to 1
    • Study completion date: Jun 1, 2020 to Jun 1, 2035
    v4
  5. Start date: Jul 10, 2019 to Nov 10, 2019
    • Primary completion date: Jan 1, 2020 to Jun 1, 2020
    • Study completion date: Jul 1, 2020 to Jun 1, 2020
    v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
Trial Details
NCT Number NCT04007276
Lead Sponsor Tulane University
Conditions
(from sponsor)		 Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
Related terms Blepharoptosis, Glaucoma, Glaucoma, Open-Angle
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov